BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
BioAge Labs, Inc.NASDAQ: BIOA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 6.1% from a year ago
Cash & equivalents stood at $241.78M at the end of Q1 FY2026, down 6.1% from a year earlier and up 28.0% from the prior quarter. Over 3 fiscal years it compounded at +89.8% a year.
Context
- Cash & equivalents amounted to 60.8% of total assets at the end of Q1 FY2026, down 14.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -6.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 188.89M USD
- Year-over-year change
- -46.7%
- 3-year CAGR
- +89.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 188.89M | -46.7% |
| FY2024 | 2024-12-31 | 354.35M | +1537.2% |
| FY2023 | 2023-12-31 | 21.64M | -21.7% |
| FY2022 | 2022-12-31 | 27.64M | — |
Cash & Equivalents vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -6.1% is the 3rd highest of 9, against a peer median of -17.1%.
- Cash & equivalents amounts to 60.8% of total assets for BIOA, versus a peer median of 29.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$364.68M CAD | +220.4% | -8.7% | 32.6% | |
BIOABioAge Labs, Inc. | Mar 2026 | $241.78M USD | -6.1% | +89.8% | 60.8% |
| Mar 2026 | $123.65M USD | -10.8% | +1.2% | 82.8% | |
| Mar 2026 | $116.64M USD | -11.5% | +0.6% | 78.7% | |
| Mar 2026 | CA$112.77M CAD | -38.8% | -27.9% | 18.7% | |
| Mar 2026 | $79.32M USD | -33.6% | -47.1% | 29.7% | |
| Mar 2026 | $48.54M USD | -22.8% | -30.4% | 43.9% | |
| Mar 2026 | $30.31M USD | -28.6% | -5.8% | 7.7% | |
| Dec 2025 | $17.47M USD | — | — | 7.5% | |
| Mar 2026 | $4.31M USD | +27.5% | -48.1% | 4.4% | |
| Peer median (excluding BIOA) | — | -17.1% | -18.3% | 29.7% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.